Alteogen Partners with Tesaro for Innovative Dostarlimab Formulation Development Alteogen has signed an exclusive deal with Tesaro to develop a subcutaneous formulation of Dostarlimab using cutting-edge Hybrozyme™ technology. The collaboration promises significant advancements in oncology.

Alteogen Partners with Tesaro for Innovative Dostarlimab Formulation Development #South_Korea #Daejeon #Alteogen #Dostarlimab #Hyaluronidase

GSK子会社TESARO、ドスタルリマブを巡りAnaptysBioを提訴 契約違反によりライセンス終了を主張 | STELLANEWS.LIFE TESARO（GSKの子会社）は、がん免疫薬ドスタルリマブ（商品名ジェンペルリ）のライセンス契約を巡り、AnaptysBioに対する訴訟をデラウェア衡平法裁判所で開始した。TESARO側は契約違反を主張し、永久的な使用権獲得とロイヤルティ支払いの半減を求めている。AnaptysBioによるライセンス取り消しの主張に対しては、根拠がないと反論している。

TESARO, a GSK subsidiary, sues AnaptysBio over the dostarlimab (Jemperli) license agreement.

🔗 Full article: stellanews.life/technology_c...

#GSK #TESARO #AnaptysBio #Jemperli #Dostarlimab #LegalDispute #Oncology #Immunotherapy #Pharma

Original post on onedaymd.com

Dostarlimab vs Pembrolizumab: Difference between Jemperli and Keytruda (2024) Key Takeaways Dostarlimab plus chemotherapy showed improved overall survival compared to pembrolizumab in advanced NSCL...

#cancer #colorectal #cancer #dostarlimab #immunotherapy #keytruda #lung #cancer #pharma […]

Dostarlimab (Jemperli) 2025 Updates: What Patients Need to Know? - OncoDaily Learn more about Dostarlimab (Jemerli), its uses, dosage, side effects, and what patients should expect during treatment.

Dostarlimab (Jemperli) 2025 Updates: What Patients Need to Know?

oncodaily.com/drugs/dostar...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Dostarlimab #Jemperli #EndometrialCancer #FDAapprovals #Immunotherapy

Dostarlimab (Jemperli) 2025 Updates: Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily Learn more about dostarlimab (jemerli), its uses in cancer treatment, side effects, dosage and what to expect.

Dostarlimab (Jemperli) 2025 Updates: Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/dostar...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Dostarlimab #Jemperli #EndometrialCancer #Immunotherapy

https://doi.org/10.1056/NEJMoa2404512 No description available

Neoadjuvant dostarlimab shows promise in a phase 2 trial, eliminating surgery for many with stage I-III dMMR solid tumors. Revolutionary! #Oncology #Dostarlimab PMID:40293177, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2404512 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪

Further analysis of the RUBY trial (Part 1) focuses on patients with dMMR/MSI-H primary advanced or recurrent EC, highlighting the consistent benefits of adding dostarlimab to CT.

@GynecologicOncology

#Onco404 #Cancer #Kanser #Immunotherapy #EndometrialCancer #dMMR #MSI #Dostarlimab

Immune Treatment May Work Against Several Cancer Types - Baby Kids Health New research shows immune treatment may work against several cancer types, offering hope beyond surgery and chemo.

A New Hope in the Fight Against Cancer 🧬✨

www.babykidshealth.com/immune-treat...

#cancertreatment #immunotherapy #healthnews #hopeforcancer #checkpointinhibitors #immunehealth #cancerresearch #dostarlimab #cancerhope #cancersurvivor #healthrevolution #fightcancer #sciencewins #health #healthnews

How Immunotherapy is Changing Cancer Treatment for Good Immunotherapy Revolutionizes Cancer Treatment, Helping Patients Avoid Surgery: 'A Game-Changer for the Future' Kelly Spill's life changed in an instant

Cancer-Free and Fertile: How Immunotherapy Changed One Woman’s Life
#Immunotherapy #CancerTreatment #CancerSurvivor #CancerResearch #BreakthroughTherapy #Dostarlimab #RectalCancer #CancerCure #CancerAwareness #HealthInnovation #MedicalBreakthrough #CancerCare #SurvivingCancer #FertilityAfterCancer

Immunotherapy drug capable of eliminating tumors in some early-stage cancers: Study Some people with early-stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, a new study shows.

Big win for early-stage cancer patients! New study shows #Dostarlimab can eliminate tumours — most patients avoided surgery altogether. Incredible progress for #Immunotherapy and real hope for the future! #TCSC #CancerResearch #Hope

abcnews.go.com/US/immunothe...

Immunotherapy replaces surgery for early-stage dMMR cancers in landmark study Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch repair-deficient (dMMR) solid tumors across multiple types. Most patients avo...

Immunotherapy replaces surgery for early-stage dMMR cancers in landmark study 🔬🧬🏥 www.news-medical.net/news/2025042... #CancerResearch #Immunotherapy #ClinicalTrial #Dostarlimab #NEJM #PrecisionMedicine #Oncology #dMMRCancers @nejm.org @mskcancercenter.bsky.social

Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab - OncoDaily Neoadjuvant dostarlimab enables nonoperative management of dMMR tumors, achieving 100% CR in rectal c-r and high organ preservation rates.

Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #dMMR #Dostarlimab #ColonCancer

Paradigm Shift? Neoadjuvant Immunotherapy Enables Organ Preservation in Early-Stage dMMR Solid Tumors!🧬

@nejm.org #NEJM

#Onco404 #Cancer #Kanser #Oncology #Immunotherapy #İmmünoterapi #PrecisionMedicine #dMMR #Dostarlimab #OrganPreservation #ClinicalTrials #RectalCancer #MedTwitter

Medicijn tegen baarmoederkanker komt in basispakket

www.transport-online.nl/82687/medici... #Agema #baarmoederkanker #basispakket #dostarlimab #immuuntherapie

"100% successful" cancer drug gets landmark FDA approval Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration granted it Breakthrough Therapy Designation status that, if successful, wi...

#Dostarlimab has been granted the breakthrough therapy designation for rectal #cancer 🧪
newatlas.com/cancer/cance...

FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer - OncoDaily FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer / cancer, dMMR/MSI-H Rectal Cancer, Dostarlimab, FDA, OncoDaily, Oncology,

FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
@fda.gov

oncodaily.com/insight/fda2...

#Cancer #dMMR/MSIH #RectalCancer #Dostarlimab #FDA #OncoDaily #Oncology #RectalCancer #Medicine #Health

"100% successful" cancer drug gets landmark FDA approval Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration granted it Breakthrough Therapy Designation status that, if successful, wi...

"100% successful" cancer drug gets landmark FDA approval! - Hugely promising cancer drug #dostarlimab is one step closer to being widely available! TCSC #rectalcancer #cancerdrug

newatlas.com/cancer/cance...

Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer | GSK Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab.

The #FDA granted #dostarlimab Breakthrough Therapy status for DMMR/MSI-H cases. Clinical trials achieved a 100% pathological complete response in selected patients.
www.gsk.com/en-gb/media/...